Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $17.2M rose 27.1% year over year, ahead of the +20.4% change in trailing-twelve-month research & development. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +34.8% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +27.1% holds above the trailing-twelve-month pace of +20.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 66.27M USD
- Year-over-year change
- +27.5%
- 4-year CAGR
- +29.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66.27M | +27.5% |
| FY2024 | 2024-12-31 | 51.96M | +71.4% |
| FY2023 | 2023-12-31 | 30.31M | +11.9% |
| FY2022 | 2022-12-31 | 27.08M | +14.1% |
| FY2021 | 2021-12-31 | 23.74M | — |
Research & Development vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 research & development of $69.93M is the 7th highest of the 11 companies compared; the peer median is $87.67M.
- Its year-over-year change of +20.4% is the 3rd highest of 11, against a peer median of -7.2%.
- Over three fiscal years its annual growth of +34.8% compares with a peer median of +4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $143.25M | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $129.09M | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $69.93M | +20.4% | +34.8% | — | |
| LTM Mar 2026 | $68M | +23.2% | +5.9% | 29.9% | |
| LTM Mar 2026 | $66.19M | -62.3% | -19.9% | 171.1% | |
| LTM Mar 2026 | $26.43M | -28.8% | -2.5% | 181.7% | |
| LTM Mar 2026 | $19.19M | -29.2% | -8.6% | — | |
| Peer median (excluding ELDN) | $87.67M | -7.2% | +4.5% | 181.7% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.74M | 27.08M | 30.31M | 51.96M | 66.27M |
| Selling, General & Admin | 13.13M | 12.7M | 12.69M | 18.61M | 16.98M |
| Operating Expenses | 36.87M | 88.43M | 43M | 70.58M | 83.25M |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| EBITDA | (36.67M) | (39.41M) | (116.16M) | (35.39M) | (45.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.87M) | (88.43M) | (43M) | (70.58M) | (83.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7K | 462K | (73.54M) | 34.82M | 37.67M |
| Income Before Tax | (36.86M) | (87.97M) | (116.54M) | (35.75M) | (45.58M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.35M) | 0 | 0 | 431K | 35K |
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| EPS (Diluted) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| Weighted Avg Shares | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
| Weighted Avg Shares (Diluted) | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.